Panatus forte syrup 7.5mg / 5ml 200ml vials + measuring spoon

Description

Composition
Active substance:
5 ml of solution contains: butamirata citrate 7.50 mg.
Excipients:
Citric acid monohydrate 12.50 mg, Sorbitol, liquid 1750.00 mg 1250.00 mg glycerol, saccharin sodium 6.25 mg, 5.00 mg of sodium benzoate, flavor, lemon 10.00 mg Sodium hydroxide 2.50 mg , water purified to 5.00 ml.
Description:
Clear liquid from colorless to pale yellow color with a characteristic lemon aroma.
Product form:
A syrup, 7.5 mg / 5 ml.
200 ml of syrup in the dark glass vial, capped with a plastic stopper and divider liquid plastic cap with tamper-evident. 1 bottle was placed in a pack carton together with measuring spoon and instructions for use.
Contraindications
Increased sensitivity to the drug, pregnancy (I term), lactation, children under 3 years, fructose intolerance.
Carefully
Pregnancy (II-III trimesters).
Dosage
1.5 mg / ml
Indications
Dry cough of any etiology, including whooping cough, cough suppressants in the preoperative and postoperative period in surgical interventions and bronchoscopy.
Interaction with other drugs
Any drug interactions are not described for butamirata.
Due to the fact that butamirata suppresses the cough reflex, avoid simultaneous use of expectorants to avoid accumulation of mucus in the airways.
In the period of the drug is not recommended Panatus forte use of ethanol as well as medicaments, CNS depressants (hypnotics, neuroleptics, tranquilizers, etc.).
Overdose
Symptoms: drowsiness, dizziness, nausea, vomiting, abdominal pain, diarrhea, irritability, impaired coordination of movements, lowering blood pressure.
Treatment: gastric lavage, activated charcoal designate, laxatives, as well as to take measures to maintain the function of the cardiovascular and respiratory systems. No antidote. Treatment is symptomatic.
pharmachologic effect
Pharmacological group:
Antitussive central action.
Pharmacodynamics:
Butamirata – active substance preparation Panatus forte, is a centrally acting antitussive agent unrelated to the opium alkaloids do not chemically or pharmacologically. Suppresses cough, having a direct effect on the cough center. It has a bronchodilator effect. It helps ease breathing, improving spirometry (reduces airway resistance) and blood oxygenation.
Pharmacokinetics:
Butamirata rapidly and completely absorbed by ingestion. After receiving 150 mg butamirata maximum concentration in the blood plasma of the main metabolite (2-phenylbutyric acid) is achieved after about 1.5 hours and is 6.4 .mu.g / ml.
With repeated use butamirata its concentration in the blood plasma remains linear and accumulation was observed.
Hydrolysis butamirata initially to 2-phenylbutyric acid and dietilaminoetoksietanola starts in blood. These metabolites also possess antitussive activity. Butamirata and its metabolites have nearly maximum (about 95%) degree of binding to plasma proteins, which leads to their long half-life (T1 / 2) and a long antitussive effect. Metabolites derived primarily by the kidneys, and acidic metabolites largely associated with glucuronic acid. T1 / 2 is 6 hours.
Pregnancy and breast-feeding
There is no data on the safety of the drug Panatus forte during pregnancy and it passes through the placental barrier. The drug is not recommended for use in the I trimester of pregnancy. In II and III trimester of pregnancy is possible to use the drug only after consulting your doctor. Given the lack of data on the allocation of butamirata in mother’s milk, the use of the drug Panatus fort during breastfeeding is not recommended.
Conditions of supply of pharmacies
Without a prescription.
side effects
Classification of the incidence of side effects of the World Health Organization (WHO): very common> 1/10, often by> 1/100 to 1/1000 to 1/10000 to 1/100000, including isolated reports.
On the part of the central nervous system (CNS): rare: drowsiness, dizziness.
From the digestive system: rare: nausea, vomiting, diarrhea.
For the skin: rare: rash.
Other: may develop allergic reactions.
special instructions
A syrup as sweeteners comprises sodium saccharin and sorbitol, can therefore be used in patients with diabetes. 5 ml syrup (1 scoop) contain 1.75 g of sorbitol. Each administration of a single dose of the drug the patient receives or sorbitol 5.25 g (3 scoops), or 3.5 g of sorbitol (2 scoops), or 1.75 mg sorbitol (1 scoop).
The drug Panatus forte is not used in patients with fructose intolerance.
If after 5-7 days of drug Panatus Fort cough does not stop, seek medical advice.
Effects on ability to perform potentially hazardous activities that require attention and fast reactions (eg, road management, work with moving machinery)
Preparation Panatus forte can cause drowsiness, so care must be taken when driving and working with complex technical devices, require high concentration and psychomotor speed reactions.
Storage conditions
At temperatures above 25 C, in the original package.
Keep out of the reach of children.
Dosing and Administration
Inside, the food.
Children 3 to 6 years: 5 ml 3 times per day; children 6 to 12 years: 10 ml 3 times per day; children over 12 years: 15 ml 3 times a day; Adults: 15 ml 4 times per day.
Use a measuring spoon (enclosed). 1 scoop = 5 ml.
If cough persists for more than 5-7 days, you should consult a doctor.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist